secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001104659-24-019884
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports Q2 FY2024 net loss $13.9M; initiates Phase 3 for RZ358 in cHI
------------------------------------------------------------------------------

- Net loss of $13.9M for Q2 FY2024, compared to $13.6M same period prior year.
- Cash, cash equivalents and investments $96.0M as of Dec 31, 2023, down from $118.4M at June 30, 2023.
- Initiated sunRIZE Phase 3 study of RZ358 in congenital hyperinsulinism; topline results expected mid-2025.
- Completed enrollment in Phase 2 study of RZ402 for diabetic macular edema; topline data expected Q2 2024.
- Appointed Daron Evans as CFO, expanding leadership for late-stage development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/0001104659-24-019884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/tm245849d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-019884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer